22:29 , Mar 12, 2019 |  BC Extra  |  Company News

Management tracks: Inovio, Sangamo, Innate

Inovio CMO Mark Bagarazzi has left the company. Inovio Pharmaceuticals Inc. (NASDAQ:INO) said a newly formed medical council -- VPs of Clinical Development Prakash Bhuyan, Jeffrey Skolnik and Scott White -- will now oversee the...
07:00 , Aug 5, 2013 |  BC Week In Review  |  Company News

Arecor, FluGen deal

Arecor will apply its Arestat formulation technology to FluGen's REDEE FLU to develop a stable formulation of the flu vaccine for storage and shipment. The deal, which will run into 2014, is funded through an...
08:00 , Nov 12, 2012 |  BC Week In Review  |  Company News

Medical Research Council pharmaceuticals news

The U.K.'s three-year, £180 million ($285.8 million) Biomedical Catalyst fund awarded £39 million ($62.4 million) across 10 universities and 22 small and medium sized enterprises (SMEs) for early stage life science research. Companies receiving funding...
08:00 , Jan 2, 2012 |  BC Week In Review  |  Company News

Arecor, Eli Lilly deal

The companies partnered to develop stable aqueous or higher concentration formulations of undisclosed protein and peptide products from Eli Lilly using Arecor's protein formulation technologies. The partners will also use the technology to improve formulations...
08:00 , Nov 14, 2011 |  BC Week In Review  |  Company News

Arecor management update

Arecor Ltd. , Cambridge, U.K.   Business: Drug delivery   Hired: Sarah Howell as COO, formerly VP of chemistry, manufacturing and controls and technical development at BTG plc  ...
07:00 , Jun 20, 2011 |  BC Week In Review  |  Company News

Arecor, GlaxoSmithKline deal

The companies partnered to develop advanced aqueous formulations of vaccines from GlaxoSmithKline's pipeline using Arecor's formulation technologies for use worldwide. Arecor will be eligible for development milestones and royalties. Details were not disclosed. Arecor Ltd....
07:00 , May 2, 2011 |  BC Week In Review  |  Company News

Arecor, Compass deal

Compass (formerly Cyplasin Biomedical Ltd.) and Arecor signed a memorandum of understanding (MOU) under which Compass' C-Pharma Inc. subsidiary will use Arecor's Arestat formulation technology to develop a heat stable HBV vaccine formulation. As part...
07:00 , Apr 19, 2010 |  BC Week In Review  |  Company News

Arecor, Genzyme deal

The companies will collaborate to develop stable formulations of labile biologics from Genzyme's pipeline using Arecor's Arestat technology. Arestat enables the formulation of labile proteins as stable aqueous preparations even at high concentrations, in situations...
00:58 , Apr 14, 2010 |  BC Extra  |  Company News

Genzyme, Arecor in formulation deal

Arecor Ltd. (Cambridge, U.K.) said it will collaborate with Genzyme Corp. (NASDAQ:GENZ) to develop stable formulations of labile biologics from Genzyme's pipeline using Arecor's Arestat technology. Arestat enables the formulation of labile proteins as stable...